Medicure Inc. (OTCMKTS:MCUJF) Stock Short Interest Jumps 396.1%

Medicure Inc. (OTCMKTS:MCUJF – Get Free Report) was the target of a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 16,610 shares, a growth of 396.1% from the October 15th total of 3,348 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily trading volume, of 29,975 shares, the days-to-cover ratio is presently 0.6 days.

Medicure Trading Up 2.2%

Shares of Medicure stock traded up $0.06 during trading hours on Friday, hitting $2.75. The company’s stock had a trading volume of 5,486 shares, compared to its average volume of 12,662. The company has a market capitalization of $28.88 million, a PE ratio of -5.39 and a beta of 1.10. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.97 and a quick ratio of 0.64. The stock has a 50 day moving average of $2.39 and a 200 day moving average of $1.24. Medicure has a 12 month low of $0.67 and a 12 month high of $3.45.

Medicure (OTCMKTS:MCUJF – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). The business had revenue of $5.36 million for the quarter, compared to the consensus estimate of $2.45 million. Medicure had a negative return on equity of 54.55% and a negative net margin of 23.14%.

About Medicure

(Get Free Report)

Medicure Inc. is a Canadian pharmaceutical company focused on developing and commercializing therapies for cardiovascular and related serious medical conditions. The company is headquartered in Winnipeg, Manitoba, and serves healthcare markets primarily through its U.S. pharmaceutical operations. Medicure’s principal commercial product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used to help reduce thrombotic cardiovascular events in patients with acute coronary syndromes, including non-ST-segment elevation acute coronary syndrome.

Read More

Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.